PDRN decreases the expression of cellular aging markers. by Jingjing Chen (293564)

Effects of GJE extract treatment decreased serum ALT and AST levels. by Natnicha Suttawong (22367172)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Effects of GJE extract treatment decreased accumulation of Col1a1. by Natnicha Suttawong (22367172)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

“…NF-κB p65 staining was higher in the NF group than controls (0.43 ± 0.11% vs. 0.11 ± 0.05%, <i><i>p</i> </i>< 0.05) and decreased with low and high GJE doses (0.22 ± 0.04% and 0.29 ± 0.10%, respectively, <i><i>p</i> </i>< 0.05), though the high-dose group remained elevated versus controls (0.29 ± 0.10% vs. 0.11 ± 0.05%, <i><i>p</i> </i>< 0.05). …”

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Mean amplitude of the Slow Delta Envelope and period of Slow Delta oscillations in the disconnected hemisphere, compared with respect to wakefulness and NREM sleep in the reference... by Michele Angelo Colombo (22446342)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Decadal mean regional hydrology. by Nic Gedney (19762301)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: